Energy News / Shareholders Foundation, Inc.

NASDAQ:SLDB Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Solid Biosciences Inc

Via: ReleaseWire

Updated 11:15 AM CDT, Wed, April 25,2018

A lawsuit was filed on behalf of investors in Solid Biosciences Inc. (NASDAQ: SLDB) shares over alleged securities laws violations.

San Diego, CA -- (SBWIRE) -- 04/25/2018 -- An investor, who purchased shares of Solid Biosciences Inc. (NASDAQ: SLDB), filed a lawsuit alleged violations of Federal Securities Laws by Solid Biosciences Inc..

Investors, who purchased shares of Solid Biosciences Inc. (NASDAQ: SLDB), have certain options and for certain investors are short and strict deadlines running. Deadline: May 29, 2018. NASDAQ: SLDB investors should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

The plaintiff alleges on behalf of purchasers of Solid Biosciences Inc. (NASDAQ: SLDB) common shares between January 25, 2018, and March 14, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 25, 2018, and March 14, 2018, the Defendants failed to disclose that Solid Biosciences' lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients, that Solid Biosciences misled investors regarding the toxicity of SGT-001, and that, as a result of the foregoing, Defendants' statements in the Registration Statement regarding Solid Biosciences' business, operations, and prospects, were materially false and/or misleading

Cambridge, MA based Solid Biosciences Inc., a life science company, engages in identifying and developing various therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, an adeno-associated viral vector-mediated gene therapy.

On January 30, 2018, an article was published by various medical experts highlighting the risks of studies using high doses of gene therapies using adeno-associated virus (AAV)-the delivery system used by Solid Biosciences' lead drug candidate SGT-001. One of the article's co-authors was Dr. James Wilson, a former member of the Solid Biosciences' advisory board.

On March 14, 2018, Solid Biosciences Inc. announced that its SGT-001 clinical trial had been put on hold by the Food and Drug Administration ("FDA") due to an adverse reaction to the treatment by one of the trial patients.

Those who purchased shares of Solid Biosciences Inc. (NASDAQ: SLDB) have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

For more information on this press release visit:

Media Relations Contact
Michael Daniels
Email: Click to Email Michael Daniels